Overview
Title
To direct the Secretary of Health and Human Services to conduct a study and submit to Congress a report on neonatal abstinence syndrome, and for other purposes.
ELI5 AI
The MIRACLE Act of 2024 wants to ask the big health boss to learn more about how medicine can affect babies when they are born. In a few years, they'll tell everyone what they found out and how to help.
Summary AI
H. R. 8905, also known as the “Maddie’s Infant Recovery And Children’s Legislative Emergency Act of 2024” or the “MIRACLE Act of 2024,” directs the Secretary of Health and Human Services to study neonatal abstinence syndrome (NAS). The study will focus on how common NAS is and the health outcomes for infants and mothers at certain care facilities. It will also identify challenges in gathering accurate NAS data and describe the services available to affected patients. Within three years, a report with study findings and recommendations will be submitted to Congress and published online.
Published
Keywords AI
Sources
Bill Statistics
Size
Language
Complexity
AnalysisAI
Editorial Commentary
General Summary of the Bill
House Bill 8905, introduced as the "Maddie’s Infant Recovery And Children’s Legislative Emergency Act of 2024" or the "MIRACLE Act of 2024," directs the Secretary of Health and Human Services to conduct a study on neonatal abstinence syndrome (NAS). This condition affects newborns who are exposed to drugs, primarily opioids, in the womb. The bill outlines a requirement for a report on the prevalence of NAS and health outcomes for infants and mothers, particularly focusing on pediatric transitional care facilities. The Secretary must identify data collection barriers and available services for those with NAS under state Medicaid plans. The findings are to be submitted to Congress and made publicly available within three years.
Summary of Significant Issues
There are several key issues identified within the bill. Firstly, the bill does not specify a budget or funding source for the mandated study, raising concerns about the adequacy of the resources that will be dedicated to this important research. Furthermore, some terms used in the bill, such as "valid, accurate, up-to-date data," lack precision, which can lead to subjective interpretations and potentially inconsistent data collection processes. Moreover, the guidelines for assessing "infant and maternal health outcomes" are not clearly defined, risking variability in research interpretations.
Another critical issue is the three-year timeline for report completion and submission, which could delay policy changes and interventions necessary for supporting infants and families affected by NAS. Additionally, while the report's publication on a public website is mandated, the bill does not detail accessibility standards, which could hinder public access to the vital information provided.
Impact on the Public
The bill aims to address the critical issue of neonatal abstinence syndrome, which significantly affects newborns and families. By mandating a study and report, it could lead to better understanding and improvements in care and policy for NAS-affected individuals. However, the lack of funding clarity and precise definitions might influence the study's effectiveness and reliability. If implemented efficiently, the bill has the potential to inform healthcare practices and policies that improve outcomes for infants exposed to drugs in utero.
Impact on Specific Stakeholders
The primary stakeholders impacted by this legislation include newborns suffering from NAS, their families, healthcare providers, and policymakers. For families and infants, successful implementation may mean improved healthcare services and support systems. For healthcare providers, the study findings could offer valuable insights into effective treatments and management strategies for NAS, potentially leading to standardized care practices.
On the other hand, policymakers and state health administrators could face challenges. The bill's vagueness regarding data standards and funding could complicate the study's execution and the integration of its findings into policy. Ensuring proper allocation of resources and clear guiding criteria will be essential for translating the bill's intentions into tangible benefits for individuals affected by NAS.
Thus, while the MIRACLE Act of 2024 has the potential to foster significant gains in understanding and addressing neonatal abstinence syndrome, successful outcomes will depend on overcoming the bill's current ambiguities and ensuring adequate resources and precise data collection and analysis standards.
Issues
Section 2: The lack of a specified budget or funding source for the study poses a risk of inadequate resources being allocated, which can undermine the effectiveness of the research and any subsequent policy decisions regarding neonatal abstinence syndrome (NAS).
Section 2: The use of vague terms such as 'valid, accurate, up-to-date data' concerning NAS prevalence may lead to inconsistent data collection and subjective interpretations. This could compromise the reliability of the study outcomes.
Section 2: No clear guidelines or criteria for evaluating 'infant and maternal health outcomes' are provided, which could result in varying and potentially conflicting interpretations of the research findings.
Section 2: The timeline of three years for the report submission to Congress after the act's enactment may delay necessary interventions and policy changes needed for patients affected by NAS, potentially prolonging their risk.
Section 2: The mandate for publication of the report on a public website lacks details regarding accessibility standards, potentially limiting public access to the critical information contained within the report.
Section 1: As a short title, this section provides no substantial information about the act’s specific contents, implications, funding, or intended beneficiaries, which challenges transparency and makes it difficult for stakeholders to understand the full scope of the legislation.
Sections
Sections are presented as they are annotated in the original legislative text. Any missing headers, numbers, or non-consecutive order is due to the original text.
1. Short title Read Opens in new tab
Summary AI
This section states that the official name of the act is the "Maddie’s Infant Recovery And Children’s Legislative Emergency Act of 2024," which can also be referred to as the "MIRACLE Act of 2024."
2. Study and report on neonatal abstinence syndrome Read Opens in new tab
Summary AI
The Secretary of Health and Human Services is required to conduct a study on neonatal abstinence syndrome (NAS) to examine how common it is and the health outcomes for mothers and infants in specific care facilities. The study will identify challenges in collecting data and available services for people with NAS, and a report with the findings must be submitted to Congress and published online within three years.